We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks.
In one of his latest appearances on CNBC’s Squawk on the Street, Jim Cramer started the morning by commenting on the latest Producer Price Index (PPI) release. The PPI, which tracks inflation upstream of the supply chain, rose by 0.2% in December and fell short of economist expectations of 0.3%. However, this didn’t lead to any significant reaction in the bond market. According to Cramer, “Carl these, the bonds just don’t want to react to anything good. Of course, we can immediately say, it’s because we’re gonna get a tough CPI number tomorrow. The fact is, is these numbers are tame. People have to start recognizing that there are some good numbers coming.”
He shared other factors that might be fueling the bond market’s performance. “House prices coming down, food coming down, but it doesn’t seem to matter,” Cramer remarked. He added “What the bonds are reacting to I think is a new administration, uh, concern about what is going to be, uh, tariffs, even though it looks like they’re going to be phased in. You know David, interest rates don’t wanna come down here. And they don’t wanna come down there’s too much issuance, there’s a belief that the next administration is much more inflationary. And David it doesn’t seem to matter what is printed, the bonds don’t want to go higher. Interest rate’s not low enough.”
Another news that has made a lot of headlines recently is TikTok’s fate in the US. Cramer believes that rather than a complete bank, there could “be a gradual diminution of the service. In other words, it’s not going to be turned off. I think that this whole idea that the Chinese Communist Party is really just a gigantic private equity firm leaves me cold. I just don’t think that they are in a situation to broker a deal.”
One person that the CNBC TV show host believes isn’t discussed enough is electric vehicle billionaire Elon Musk. “I mean, Carl, it’s so exciting to talk about Elon Musk. I mean we haven’t talked about Elon, you know you have to wait maybe to nine o’ four to talk about Elon Musk. I just say we do it at the very top,” believes Cramer. He added “We have Elon Musk being the most important, well, he’s, he’s co-president right now which I think is a little absurd.. . . this man has become, Carl, a nation-state within. He’s a state within a state.”
On the topic of markets, Cramer was appreciative of the fact that the market and equal-weighted benchmark S&P indexes are up identically over the last six months “Well look I, that’s good news actually. We want to have broader leadership,” he remarked. However, without Wall Street’s favorite AI stock, Cramer believes “you have a market that’s kind of ruthless. . . David, you know that this market survives on NASDAQ fuel and not on Dow fuel. And yet people still insist on talking about the Dow.”
Finally, Cramer has also spent quite a bit of time discussing social media CEO Mark Zuckerberg’s appearance on the Joe Rogan Experience podcast. This time around, he shared “I’ll go right to Joe Rogan. I’ll be five hours in Joe Rogan. One of the most jarring things about the Joe Rogan interview was that he said he had to take a bathroom break. Well, there’s professionalism personified.” Cramer also commented on whether 38% is too much for an interviewer to speak. Taking a mixed view, he stated “I think it is. I used to put a stopwatch to my show Kudlow & Cramer. I got to speak 38% of the time so you know what, maybe it’s not so bad.”
Our Methodology
To make our list of the stocks that Jim Cramer talked about, we listed down all the stocks he mentioned during CNBC’s Squawk on the Street aired yesterday.
For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds invest in? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
Number of Hedge Fund Holders In Q3 2024: 106
Eli Lilly and Company (NYSE:LLY) is one of the hottest healthcare stocks on the market courtesy of its weight loss drugs. The show dedicated quite a bit of airtime to the firm as Cramer was covering the JPMorgan Healthcare Conference as it was being aired. He interviewed Eli Lilly and Company (NYSE:LLY)’s CEO David Ricks as part of the coverage, and commented on the stock before and after the interview. Here’s what Cramer said:
“Yeah, I think that you’re gonna see some numbers at [a] level of growth that that’s unheard of frankly for a new drug. Some numbers to be put out that I think are really what you would get at for ten years. Blockbuster, blockbuster, I mean $25 billion. Now initially people are going to sell the stock, they’re gonna sell the stock because somehow they believe that it’s gonna miss the fourth quarter. The fourth quarter was always etched in stone. It was going to not be as good as their numbers. So David, it’s very hard to have a surprise when we already knew what they were going to do and it was in line. I suggest that people listen to our interview with David Ricks and figure out what 2025’s going to be, because 2024, already in the history books, doesn’t matter to the stock.”
“[on guidance of 32% midpoint revenue growth for 2025] Yeah, 32% very good numbers, I think what we’re going to have to focus on David, we’re going to have to ask Mr. Ricks about inventory, how much was there to sell, the demand side is insane, I care about demand more than I care about what these numbers are indicating. Let them sell, I look at it almost as you would on a trading desk, let them sell it. Let the uninformed people sell it. And then look at the size of this market, realize that we’re in its infancy. And its infancy is already so much bigger than any drug I’ve ever seen. I think you have to be on the horse that is Eli Lilly.”
“I think the problem with Eli Lilly is, as David Ricks admitted, there’s been some mistakes. They have not done the launch as easily as people thought. I say as I said in the beginning, let em sell it. I mean in the end this is the, GLP-1s the greatest drug of all time. It will be used for multiple indications. People wanted David Ricks to come out here and say, you know what, next year’s going to be far bigger than expected. He doesn’t play that game. It has never been the way he does things. We sold some stock when it was in the eight hundred, nine hundred, for my charitable trust. All I can say is, now I’m restricted, I can’t buy it back right now. I wish I could, down eight percent. I think it goes down ten percent as we get rid of people who don’t understand the story. And then people come in who understand the story, and they’ll buy the stock.”
Overall LLY ranks 4th on our list of the stocks Jim Cramer recently discussed. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article is originally published at Insider Monkey.
